Cytek Biosciences (CTKB) Shares Outstanding (Diluted Average) (2020 - 2025)
Cytek Biosciences filings provide 6 years of Shares Outstanding (Diluted Average) readings, the most recent being $126.9 million for Q2 2025.
- On a quarterly basis, Shares Outstanding (Diluted Average) fell 3.24% to $126.9 million in Q2 2025 year-over-year; TTM through Jun 2025 was $126.9 million, a 3.24% decrease, with the full-year FY2023 number at $135.3 million, down 2.37% from a year prior.
- Shares Outstanding (Diluted Average) hit $126.9 million in Q2 2025 for Cytek Biosciences, down from $131.1 million in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $138.6 million in Q4 2022 to a low of $36.2 million in Q2 2021.
- Median Shares Outstanding (Diluted Average) over the past 5 years was $132.8 million (2022), compared with a mean of $121.1 million.
- Biggest five-year swings in Shares Outstanding (Diluted Average): surged 69.93% in 2022 and later dropped 3.49% in 2024.
- Cytek Biosciences' Shares Outstanding (Diluted Average) stood at $81.5 million in 2021, then skyrocketed by 69.93% to $138.6 million in 2022, then fell by 2.37% to $135.3 million in 2023, then decreased by 3.08% to $131.1 million in 2024, then fell by 3.19% to $126.9 million in 2025.
- The last three reported values for Shares Outstanding (Diluted Average) were $126.9 million (Q2 2025), $131.1 million (Q3 2024), and $131.2 million (Q2 2024) per Business Quant data.